Pfizer Inc and BioNTech SE said on Monday their Covid-19 vaccine induced a robust immune response in 5- to 11-year-olds, and they plan to ask for authorization to use the vaccine in children in that age range in the United States, Europe, and elsewhere as soon as possible.
The U.S. Food and Drug Administration is preparing to authorize Pfizer Inc and German partner BioNTech SE's COVID-19 vaccine for adolescents aged between 12 and 15 years by early next week, the New York Times reported on Monday, citing federal officials familiar with the agency's plans.
The United States is preparing for the possibility that a booster shot will be needed between nine to 12 months after people are initially vaccinated against Covid-19, a White House official said on Thursday.
Pfizer and BioNTech's Covid-19 vaccine is safe, effective and produces robust antibody responses in 12- to 15-year olds, the companies said last week, paving the way for them to seek U.S. and European approval to use the shot in this age group within weeks.
Gov. Andrew Cuomo asked Pfizer Inc Chief Executive Albert Bourla on Monday if the state could buy Covid-19 vaccine doses directly from the U.S. drugmaker.